BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
Vote In favor of Your #1 Cell phones- Getting ready for a Mechanized World: 10 Positions That computer based intelligence Could Dominate
- The Best Internet based Courses for Expertise Improvement
- Most loved Well known Accessory Styles For 2024
- Virtual Route d: A Survey of \Exploring On the web Stages\ Web Administration
- Vacation spots in America
- Jesse Jackson hospitalized, under observation for a neurodegenerative condition
- Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- Surveys of Thrillers That Re-imagined the Class
